Brian M. Culley - 19 Dec 2025 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Signature
/s/ Brian M. Culley
Issuer symbol
LCTX
Transactions as of
19 Dec 2025
Net transactions value
-$561
Form type
4
Filing time
19 Dec 2025, 21:55:05 UTC
Previous filing
12 Mar 2025
Next filing
13 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Culley Brian M President and CEO, Director C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD /s/ Brian M. Culley 19 Dec 2025 0001310683

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares Award +8,925 +4.2% 222,469 19 Dec 2025 Direct F1, F2
transaction LCTX Common Shares Tax liability $561 -334 -0.15% $1.68 222,135 19 Dec 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units ("RSUs") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis.
F2 Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof.
F3 Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 8,925 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.